Company Overview - Zai Lab Limited is a patient-centric, innovative global biopharmaceutical company focused on commercialization, operating in China and globally, aiming to provide optimal and first-in-class drugs for patients with cancer, autoimmune diseases, infectious diseases, and central nervous system disorders [2] Financial Performance - As of March 31, 2025, Zai Lab achieved total revenue of 764 million yuan, representing a year-on-year growth of 22.19% - The company reported a net profit attributable to shareholders of -348 million yuan, with a year-on-year increase of 9.41% - Gross margin stood at 63.71%, and the debt-to-asset ratio was 30.9% [1] Stock Performance - On June 12, the Hang Seng Index fell by 1.36%, closing at 24,035.38 points - Zai Lab's stock closed at 34.55 HKD per share, up 8.65%, with a trading volume of 19.11 million shares and a turnover of 661 million HKD, showing a volatility of 11.48% - Over the past month, Zai Lab's cumulative increase was 34.75%, and since the beginning of the year, it has risen by 52.15%, outperforming the Hang Seng Index by 21.47% [1] Valuation Metrics - The average price-to-earnings (P/E) ratio for the pharmaceutical and biotechnology industry (TTM) is 4.2 times, with a median of 6.01 times - Zai Lab's P/E ratio is -17.95 times, ranking 108th in the industry - Comparatively, other companies in the health sector have P/E ratios of 0.56 times (Daiichi Sankyo Co., Ltd.), 0.68 times (Jiangsu Hengrui Medicine Co., Ltd.), 1.6 times (King's Ray Biotechnology), 3.08 times (Dongrui Pharmaceutical), and 3.16 times (Chia Tai Tianqing Pharmaceutical) [1] Analyst Ratings - Kaiyuan Securities Co., Ltd. has given Zai Lab a "Buy" rating [1]
再鼎医药（09688.HK）6月12日收盘上涨8.65%，成交6.61亿港元